OUTLOOK THERAPEUTICS INC is trading at $1.30 (up 6.6%) after a key FDA appeal win that enables the resubmission of its Biologics License Application (BLA) for ONS-5010/LYTENAVA.
- The regulatory victory provides a clear path forward for the company's lead ophthalmic candidate, sparking significant investor interest.
- Ascendiant Capital maintained its Buy rating and raised its price target on the news, further fueling the upward move.
- Shares are seeing continued follow-through momentum from last week’s sharp gains related to the same regulatory catalyst.